ONCE DAILY CEFPODOXIME SUSTAIN RELEASE

Cefpodoxime is a oral third generation cephalosporin active against most of

gram positive and gram negative bacteria except Pseudomonas, B. fragilis
and Entrococcous. Clinical studies have confirmed efficacy of cefpodoxime in
acute otitis media, sinusitis and tosillopharyngitis.

Once daily administration and safety profile increases compliance and

decreases failure rate. It has a role as switch over therapy from intravenous
ceftriaxone in serious respiratory tract infections (RTIs).

In areas where common respiratory pathogens show decreased sensitivity to

penicillins and macrolides cefpodoxime can be used as empirical first line
therapy in respiratory tract infections. It seems to be a promising molecule in
pediatric typhoid fever because of its excellent activity against Salmonella
species but clinical trials are limited.

Cefpodoxime is only oral cephalosporin which covers Staph aurius.

Cefpodoxime is equally efficacious to I.V ceftrioxone with 90% cure rate hence
ideal switch over therapy in serious bacterial infections. Clinical success rate
with co-amoxyclave is 82%, Cefuroxime 79%, cefixime 86% and for
Cefpodoxime is 98%.

Dosage is 8 mg/kg/day ONCE for 5 days whereas co-amoxyclave is 40

mg/kg/day TDS for 10-15 days. Tissue penetration of cefpodoxime is twice to
that of Cefixime. Cefpodoxime is ten times more potent than cefixime against
S.pneumonia. There is no dosage adjustment for liver failure patient unlike
co-amoxyclave. There is no food drug interaction unlike co-amoxyclave.

Cephalosporin is the only antibiotic segment which is safe in pregnancy and

lactation. It safe up to 3 months baby therefore used in pediatric Typhoid
fever. Most admired antibiotic in the world in terms of efficacy and safety,
2005 Nov-Dec J Drug Dermatol

Cefpodoxime has more mileage in terms of efficacy, safety and dosage

convenience in comparison to other available treatment options..

Cefpodoxime is an ideal choice for RTI, ENT and Soft skin tissue infection.
Cefpodoxime is cell wall synthesis inhibitor antibiotic. Cefpodoxime treats
typhoid more easily and safely because of dual mode of action and better
spectrum of activity. Cefpodoxime has an added advantage in treating
 bacterial infection safely in geriatric, pediatric, pregnancy, lactating mother,
impaired renal failure and in impaired kidney failure patients.

The Cefpodoxime in sustain release would be boon for the medical fraternity
in terms of convenient once a dose in treating spectrum betalactamase
infection. This sustain release combination could be an economical for the
patient and easy to prescribe the physician as well.

Reference

1. Manzoni P, Esposito S, Gallo E, Gastaldo L, Farina D, Principi N. J

Chemother. 2009 Feb;21(1):68-73.
2. Mendelman PM, Del Beccaro MA, McLinn SE, Todd WM.J Pediatr. 1992
Sep;121(3):459-65. Erratum in: J Pediatr 1993 Mar;122(3):502.
3. Fukuhara H, Irabu Y, Kakazu T, Nakamura H, Shigeno Y, Saito A, Owan T,
Oshiro H, Miyaguni T, Nakasone K, et al.Jpn J Antibiot. 1993 Jan;46(1):53-9.
Japanese
4. Stevens DL, Pien F, Drehobl M.Diagn Microbiol Infect Dis. 1993
Feb;16(2):123-9.

MEHER PHARMA INTERNATIONAL

B-6/151, SECTOR-3, NEAR JAIPURE GOLDEN HOSPITAL, DELHI-85

DR.MOHD SHAHBAZ ALAM-9818131498, shahbaz@meherpharma.com